196 related articles for article (PubMed ID: 11751483)
21. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
22. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
[TBL] [Abstract][Full Text] [Related]
23. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
24. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
Kelly WK; Zhu AX; Scher H; Curley T; Fallon M; Slovin S; Schwartz L; Larson S; Tong W; Hartley-Asp B; Pellizzoni C; Rocchetti M
Clin Cancer Res; 2003 Jun; 9(6):2098-107. PubMed ID: 12796374
[TBL] [Abstract][Full Text] [Related]
25. Overcoming bcl-2- and p53-mediated resistance in prostate cancer.
DiPaola RS; Aisner J
Semin Oncol; 1999 Feb; 26(1 Suppl 2):112-6. PubMed ID: 10190792
[TBL] [Abstract][Full Text] [Related]
26. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.
Badros AZ; Goloubeva O; Rapoport AP; Ratterree B; Gahres N; Meisenberg B; Takebe N; Heyman M; Zwiebel J; Streicher H; Gocke CD; Tomic D; Flaws JA; Zhang B; Fenton RG
J Clin Oncol; 2005 Jun; 23(18):4089-99. PubMed ID: 15867202
[TBL] [Abstract][Full Text] [Related]
28. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
Samelis GF; Kalofonos H; Adamou A; Kosmides P; Skarlos D; Aravantinos G; Kiamouris C; Adimchi O; Fountzilas G; Dimopoulos AM
Urology; 2005 Aug; 66(2):382-5. PubMed ID: 16098366
[TBL] [Abstract][Full Text] [Related]
29. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
[TBL] [Abstract][Full Text] [Related]
30. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W
J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070
[TBL] [Abstract][Full Text] [Related]
31. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
Rheingold SR; Hogarty MD; Blaney SM; Zwiebel JA; Sauk-Schubert C; Chandula R; Krailo MD; Adamson PC;
J Clin Oncol; 2007 Apr; 25(12):1512-8. PubMed ID: 17442993
[TBL] [Abstract][Full Text] [Related]
32. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Fizazi K; De Bono JS; Flechon A; Heidenreich A; Voog E; Davis NB; Qi M; Bandekar R; Vermeulen JT; Cornfeld M; Hudes GR
Eur J Cancer; 2012 Jan; 48(1):85-93. PubMed ID: 22129890
[TBL] [Abstract][Full Text] [Related]
33. Genasense (Genta Inc).
Banerjee D
Curr Opin Investig Drugs; 2001 Apr; 2(4):574-80. PubMed ID: 11566020
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
Galatin PS; Advani RH; Fisher GA; Francisco B; Julian T; Losa R; Sierra MI; Sikic BI
Invest New Drugs; 2011 Oct; 29(5):971-7. PubMed ID: 20349264
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy.
Pusztai L; Holmes FA; Fraschini G; Hortobagyi GN
Cancer Chemother Pharmacol; 1999; 43(1):86-91. PubMed ID: 9923546
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.
Vaishampayan U; Glode M; Du W; Kraft A; Hudes G; Wright J; Hussain M
Clin Cancer Res; 2000 Nov; 6(11):4205-8. PubMed ID: 11106233
[TBL] [Abstract][Full Text] [Related]
37. Technology evaluation: G-3139.
Banerjee D
Curr Opin Mol Ther; 1999 Jun; 1(3):404-8. PubMed ID: 11713806
[TBL] [Abstract][Full Text] [Related]
38. Combined use of antisense oligonucleotides and chemotherapeutics in the treatment of refractory prostate cancer.
Baltogiannis D; Charalabopoulos K; Giannakopoulos X; Karakosta A; Sofikitis N
Exp Oncol; 2005 Jun; 27(2):91-3. PubMed ID: 15995623
[TBL] [Abstract][Full Text] [Related]
39. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model.
Miyake H; Hara S; Arakawa S; Kamidono S; Hara I
Br J Cancer; 2001 Mar; 84(6):859-63. PubMed ID: 11259104
[TBL] [Abstract][Full Text] [Related]
40. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.
O'Brien SM; Cunningham CC; Golenkov AK; Turkina AG; Novick SC; Rai KR
J Clin Oncol; 2005 Oct; 23(30):7697-702. PubMed ID: 16186597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
